menu search

APLM / Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline
Apollomics is a small company with a pipeline of c-Met targeting small molecule TKIs for various cancers. Their lead candidate, Vebreltinib, is in phase 2 trials for NSCLC, GBM, and other solid tumors. They also have a second asset, APL-106, which is a specific E-Selectin antagonist being explored as a therapeutic target in certain types of cancer metastasis. Read More
Posted: Aug 29 2023, 06:21
Author Name: Seeking Alpha
Views: 042626

APLM News  

Why Is Apollomics (APLM) Stock Up 113% Today?

By InvestorPlace
October 27, 2023

Why Is Apollomics (APLM) Stock Up 113% Today?

Apollomics (NASDAQ: APLM ) stock is rising higher on Friday as the shares bounce back on recent study results. Those study results cover the “effic more_horizontal

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

By Seeking Alpha
August 29, 2023

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Apollomics is a small company with a pipeline of c-Met targeting small molecule TKIs for various cancers. Their lead candidate, Vebreltinib, is in pha more_horizontal

The 7 Most Promising Penny Stocks to Buy in June

By InvestorPlace
June 7, 2023

The 7 Most Promising Penny Stocks to Buy in June

Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which youn more_horizontal


Search within

Pages Search Results: